|
|
||||||||
CardioPulmonary Research Institute, Departments of Pediatrics, Pulmonary Medicine, and Thoracic and Cardiovascular Surgery, Winthrop-University Hospital, State University of New York at Stony Brook School of Medicine, Mineola, New York 11501
| |
ABSTRACT |
|---|
|
|
|---|
Exogenous nitric oxide (NO) is being tested clinically for the treatment of pulmonary hypertension in infants and children. In most cases, these patients receive simultaneous oxygen (O2) therapy. However, little is known about the combined toxicity of NO+hyperoxia. To test this potential toxicity, human alveolar epithelial cells (A549 cells) and human lung microvascular endothelial lung cells were cultured in room air (control), hyperoxia (95% O2), NO (derived from chemical donors), or combined hyperoxia+ NO. Control cells grew normally over a 6-day study period. In contrast, cell death from hyperoxia was evident after 4-5 days, whereas cells neither died nor divided in NO alone. However, cells exposed to both NO and hyperoxia began to die on day 2 and died rapidly thereafter. This cytotoxic effect was clearly synergistic, and cell death did not occur via apoptosis. As an indicator of peroxynitrite formation, nitrotyrosine-containing proteins were assayed using anti-nitrotyrosine antibodies. Two protein bands, at molecular masses of 25 and 35 kDa, were found to be increased in A549 cells exposed to NO or NO+hyperoxia. These results indicate that combined NO+hyperoxia has a synergistic cytotoxic effect on alveolar epithelial and lung vascular endothelial cells in culture.
apoptosis; oxygen toxicity; persistent pulmonary hypertension of the newborn; lung injury
| |
INTRODUCTION |
|---|
|
|
|---|
NITRIC OXIDE (NO) is an inorganic, highly reactive, and rapidly diffusible gas that was discovered to be the endothelium-derived relaxation factor (13, 18). Endogenous NO is produced by many cell types and is important in regulating normal basal vasomotor tone. In the lung, NO produced by the pulmonary endothelium is responsible for the fall of pulmonary vascular resistance soon after the birth of the newborn infant (1). High vascular pressure persists when this response fails to occur, resulting in persistent pulmonary hypertension of the newborn. Exogenously administered NO is also a potent vasodilator (5, 7, 12, 16, 20, 22). Its mechanism of action is primarily through the activation of guanylate cyclase, which increases the production of guanosine 3',5'-cyclic monophosphate and results in smooth muscle relaxation (24). A dynamic cycle exists in which hemoglobin is S-nitrosylated in the lung when red blood cells are oxygenated, and the NO group is released during arterial-venous transit. Changes in oxygen (O2) tension might also regulate NO delivery because NO release is facilitated by deoxygenation (14).
Various early reports (16, 20) showed that inhalation of NO together with high inspired concentrations of O2 significantly improved oxygenation in infants with persistent pulmonary hypertension of the newborn and in some cases reduced the need for extracorporeal membrane oxygenation. NO has also been reported to improve oxygenation in premature infants with respiratory distress syndrome and in full-term infants with congenital heart disease and diaphragmatic hernia (5, 12). Clinical use of NO in the United States is currently limited to experimental protocols for treating extremely sick patients with primary diseases of the lungs or heart. These patients are invariably receiving high concentrations of O2 (hyperoxia) to maintain adequate oxygenation. Hyperoxia alone is cytotoxic (9). In most instances, NO is added to the existing flow of O2. Recent evidence suggests that the combined use of NO+hyperoxia has adverse effects on lung surfactant (10, 11, 19). However, there is a paucity of studies addressing whether the combination of inhaled NO+hyperoxia can injure cells or organs. Here we report that this combination produces synergistic cytotoxicity in cultured alveolar epithelial and pulmonary microvascular endothelial cells.
| |
METHODS |
|---|
|
|
|---|
Cell culture and cytotoxicity assays. Human alveolar epithelial A549 cells (American Type Culture Collection CCL-185) were grown in Ham's F-12-K medium (GIBCO BRL, Life Technologies, Gaithersburg, MD) supplemented with 10% heat-inactivated fetal bovine serum, 2 mM glutamine, 100 U/ml of penicillin, and 100 µg/ml of streptomycin. Human microvascular endothelial lung cells (HMVEC-L) (Clonetics, San Diego, CA) were grown in endothelial growth medium (Microvascular, BulletKit, Clonetics). Cells were maintained at 37°C in 95% room air-5% CO2 in a humidified chamber. A549 cells were seeded at 6 × 104 cells/ml, and HMVEC-L were seeded at 4.8 × 104 cells/ml. Cells adhered overnight in 35-mm culture dishes. The next day, the dishes were divided into four groups, and cells were grown in 95% room air-5% CO2 (control), room air+NO, 95% O2-5% CO2 (hyperoxia), and hyperoxia+NO. NO was generated in culture medium using one of two NO donors: S-nitroso-N-acetylpenicillamine (SNAP; Biomolecular Research Laboratories, Plymouth Meeting, PA) or 2,2'-(hydroxynitrosohydrazono)-bis-ethanamine (DETA NONOate; Cayman Chemical, Ann Arbor, MI). NO levels generated in culture medium were measured using the Iso-NO meter (World Precision Instruments, Sarasota, FL). Media, NO donors, and gasses were refreshed once each day. The total cell count and number of live cells were determined daily with a hemacytometer; live cells were distinguished by the exclusion of trypan blue dye.
Assays of apoptosis. Cells were grown on glass coverslips and treated as described above for 3 days. The protocol utilized for the terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling (TUNEL) assay was as described previously (15). Fluorescent TUNEL reagents were obtained from Boehringer Mannheim. Cells were dual labeled with 4 µg/ml of the DNA-binding dye 4',6-diamidino-2-phenylindole dihydrochloride (DAPI; Boehringer Mannheim, Indianapolis, IN) for 5 min at room temperature. With the use of a Nikon Optiphot microscope with epifluorescence and an ultraviolet-2A filter (Nikon Instruments, Melville, NY), apoptotic nuclei were identified as smaller and brighter objects than their normal counterparts (15).
Western blot analysis. Cells were washed three times with phosphate-buffered saline (PBS) and lysed in 300 µl of lysis buffer [10 mM tris(hydroxymethyl)aminomethane (Tris) hydrochloride, pH 6.8, 10 µg/ml of aprotinin, and 1 mM phenylmethylsulfonyl fluoride] per dish. Cellular proteins were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis using 4-20% acrylamide gradient gels (BioRad Laboratories, Hercules, CA) under reducing conditions (17). Proteins were transferred to Immobilon polyvinylidene fluoride membranes (Millipore, Bedford, MA) at 24 V for 30 min using an electrophoretic blotting apparatus (Idea Scientific, Minneapolis, MN). Nonspecific binding to the membrane was blocked by incubation with 5% nonfat dry milk overnight at 4°C. Nitrotyrosine-containing proteins were immunodetected using 1 µg/ml of rabbit polyclonal anti-nitrotyrosine antibody (Upstate Biotechnology, Lake Placid, NY) in PBS and 0.1% Tween 20. A goat anti-rabbit secondary antibody [immunoglobulin G (IgG)] conjugated to alkaline phosphatase (Boehringer Mannheim) was used to detect the primary antibody and was visualized by nitro blue tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate in alkaline phosphate buffer (100 mM Tris · HCl, pH 9.5, and 50 mM MgCl2).
Immunocytochemistry. Cells cultured on coverslips were rinsed with ice-cold PBS and fixed and permeabilized for 30 min in 2% paraformaldehyde and 0.1% Triton X-100. Cells were incubated for 1 h at 4°C with 3 µg/ml of the same rabbit polyclonal anti-nitrotyrosine antibody. Primary antibody was detected with 240 µg/ml of goat anti-rabbit IgG conjugated with rhodamine (Organon Teknika, Durham, NC). The cellular localization of the antigen was visualized using a G-2A filter (Nikon) attached to a fluorescent microscope.
| |
RESULTS |
|---|
|
|
|---|
To compare the cytotoxicity of combined NO+hyperoxia with either agent alone, cells were divided into four groups: room air (control), room air+NO, hyperoxia (95% O2-5% CO2), and a combination of hyperoxia+NO. A series of preliminary experiments was performed to identify conditions under which the NO donors would not be overtly cytotoxic to A549 cells or HMVEC-L. On the basis of these experiments, we determined that the highest concentration that caused virtually no cell death over the time course of 1 wk was 2 mM SNAP or 0.5 mM DETA NONOate (data not shown). In the culture medium used, 2 mM SNAP yielded peak levels of NO (4.4 µM) after 2 h, and NO levels gradually declined to baseline over the next 10 h (Fig. 1). As expected, control untreated cells increased in number during the entire experiment when cultured in room air alone. Figure 2 shows that there was no appreciable cell death in SNAP alone during the experiment, although the cell population did not increase. Similarly, cell death was minimal in the hyperoxia group until day 4. Unlike these relatively modest cytotoxic effects, cells exposed to the combination of NO+hyperoxia died rapidly (Fig. 2). Cell death in large numbers was evident as early as day 2, and the remaining cells died soon thereafter. This cytotoxicity was clearly synergistic, with the death rate exceeding any additive effect. To determine whether the synergistic cytotoxicity was due specifically to NO+hyperoxia and not to a nonspecific artifact of the NO donor SNAP, the experiment was repeated using a different NO donor, DETA NONOate. A concentration of 0.5 mM was chosen on the basis of several preliminary experiments that showed no cytotoxicity at this concentration over a period of 6 days. NO release from 0.5 mM DETA NONOate was slower but more sustained than with 2 mM SNAP (Fig. 1). Figure 3 shows that the NO donor alone had few cytotoxic effects but was synergistic when used in combination with hyperoxia. This observation confirms the earlier results with SNAP and supports the conclusion that synergistic cytotoxicity was due to hyperoxia+NO and not a by-product of either NO donor. To determine whether cell death synergy is limited to these transformed cells or occurs in any primary lung cells, the experiments were repeated using primary HMVEC-L. Figure 4 shows that synergistic cytotoxicity was evident in these primary cells, suggesting that the effects of O2+NO might be widespread. HMVEC-L cultured under these conditions were relatively resistant to both NO and hyperoxia, and the synergistic death did not occur until day 6.
|
|
|
|
To determine whether combined NO+hyperoxia causes cell death via apoptosis, two different assays of apoptosis were utilized. DAPI is a DNA-binding dye that is fluorescent when bound to DNA and excited by ultraviolet light. Apoptotic nuclei are clearly distinguished from normal nuclei on the basis of their intense fluorescence and much smaller size (15). Figure 5 shows that apoptosis was not evident after culture in NO alone, hyperoxia alone, or combined NO+hyperoxia. As a positive control, cells were exposed to a level of H2O2 that is known to induce widespread apoptosis in these cells (15). Figure 5 shows widespread apoptosis under these conditions. To independently confirm these observations, apoptosis was also studied with the TUNEL assay, which labels 3'-COOH ends of DNA in chromatin, which result from endonucleolytic cleavage occurring during apoptosis (15). Figure 5 shows that cells cultured in NO+hyperoxia, in NO alone, and in hyperoxia alone were all TUNEL negative, whereas cells exposed to H2O2 (positive control) clearly demonstrate apoptosis. These data confirm the observation that hyperoxia does not cause epithelial cell apoptosis (15) and indicate that combined NO+hyperoxia also causes cell death via nonapoptosis.
|
Hyperoxia is known to cause intracellular accumulation of reactive
O2-derived intermediates including
the superoxide anion (
) (23).
Superoxide can react rapidly with NO to form peroxynitrite
(ONOO
), an extremely
reactive and toxic molecule (3). Although
ONOO
is too reactive to
measure directly, one of its reaction products, nitrotyrosine, which
forms when ONOO
donates a
nitro group to tyrosine residues in cellular proteins, is stable and
detectable in tissues and cells. To determine whether the synergistic
cytotoxicity of NO+hyperoxia is associated with increased
nitrotyrosine, immunocytochemistry was performed using anti-nitrotyrosine antibodies. Nitrotyrosine was barely detected by
immunofluorescence in cells grown in room air alone or in hyperoxia (Fig. 6). Cells cultured in NO showed
diffuse immunofluorescence, suggesting the accumulation of
nitrotyrosine. However, cells grown in combined NO+hyperoxia showed a
more intense signal, perhaps because the intracellular
immunofluorescence pattern became eccentric (Fig. 6). Cells incubated
with secondary antibodies alone showed no signal (not shown).
|
To gain a further understanding of the nature of the proteins modified
by ONOO
, cellular proteins
were size fractionated on polyacrylamide gels and assayed on Western
blots using anti-nitrotyrosine antibodies. Figure
7 shows that immunoreactive proteins were
barely detected in either control cells cultured in room air or cells
exposed to hyperoxia alone. In contrast, cells exposed to combined
NO+hyperoxia showed a notable increase in the levels of two protein
bands, migrating at 25 and 35 kDa. Interestingly, cells cultured in NO alone also showed immunoreactive proteins at 25 and 35 kDa. The specificity of this result was confirmed with control assays by incubating Western blots with nonimmune rabbit IgG or with
anti-nitrotyrosine antibodies preabsorbed with excess (10 mM)
nitrotyrosine (data not shown).
|
| |
DISCUSSION |
|---|
|
|
|---|
Inhaled NO therapy is currently being studied in patients also receiving concurrent treatment with O2 and mechanical ventilation, yet there is a paucity of data from animal or cell culture studies on the combined effects of these two agents. We have performed a set of experiments in cultured alveolar epithelial and lung microvascular endothelial cells that demonstrates that the combination of NO+hyperoxia is much more cytotoxic than either agent alone. These observations are important because they demonstrate that the beneficial effects of inhaled NO therapy have the potential to be accompanied by deleterious side effects when combined with hyperoxia. Although there is some evidence that endogenous NO or lower doses of exogenous (10 parts/million) NO improved alveolar liquid clearance, higher doses of exogenous NO (100 parts/million) increased vascular permeability to protein, and survival of rats exposed to hyperoxia was not improved by inhaled NO (8). Together with reports of lung injury and surfactant dysfunction in animals receiving concurrent inhaled NO+hyperoxia (10, 11, 19), these observations suggest that there is a potential for damage to lung epithelium and endothelium from this therapy. It may therefore be important to minimize exposure to these agents when administered clinically.
The precise relationship between these cell culture experiments and the
experimental use of NO in patients is not yet clear, and the full range
of NO doses and O2 levels is yet
unexplored. The levels used in these experiments are probably high
relative to those experienced by cells in intact lungs. Moreover, the
effects of NO+hyperoxia on the multiple cell types of intact lungs are likely to differ in many ways from the effects we observed in homogeneous cell culture. Because NO and
ONOO
are highly reactive,
we postulated that the cells would die via apoptosis, as is typically
reported to occur in response to oxidative cellular damage (2, 4, 6,
21, 23). However, the mode of cell death by combined NO+hyperoxia was
not apoptosis, as shown by nuclear size, DNA staining intensity, and
TUNEL assay. The capacity of these cells to undergo typical
oxidant-induced apoptosis is well described (15) and was evident in
positive control experiments when the cells were exposed to
H2O2.
The mode of cell death from combined NO+hyperoxia may be similar to the
mode of death from hyperoxia alone (15), although the time course of
cell death was much more rapid when exogenous NO was present. However,
the observed nonapoptotic cell death was substantially slower in
combined NO+hyperoxia relative to oxidant-induced apoptosis (2 or more days vs. 4 h), consistent with the nuclear morphology and
TUNEL assays showing the absence of apoptosis.
The observation that intense immunofluorescence with anti-nitrotyrosine
antibody was correlated with severe cytotoxicity suggested that
ONOO
may have a role in
mediating the cytotoxic effects shown here. The Western blot analysis
further suggested that the specific nitration of two proteins with
molecular masses of 25 and 35 kDa may be relevant. However, nitration
of bands of the same size also occurred in the cells grown in NO alone,
indicating that nitration of these proteins is not sufficient for
synergistic cell death. Moreover, on the basis of the fact that
ONOO
formation requires
superoxide (10), this observation suggests that sufficient superoxide
is produced in these cells to generate some
ONOO
, even when cultured in
room air. The observation that nitrotyrosine immunofluorescence
appeared notably enhanced is difficult to understand in the absence of
a large increase in the abundance of nitrotyrosine-containing proteins
on Western blots. Perhaps
ONOO
-modified proteins
become translocated in cells in NO+hyperoxia, resulting in eccentric
fluorescence. Alternatively, changes in conformation (perhaps increased
denaturation) may underlie the enhanced cellular immunofluorescence.
Further work is needed to identify these proteins and to determine
whether they have a role in cytotoxicity.
| |
ACKNOWLEDGEMENTS |
|---|
We thank Dr. Warren Rosenfeld for reviewing the manuscript and Lisa Underwood and Sona Narula for administrative help.
| |
FOOTNOTES |
|---|
This work was funded in part by National Heart, Lung, and Blood Institute Grant HL-02791, the American Lung Association, March of Dimes Birth Defects Foundation Basic Grant FY-97-0590, and Winthrop-University Hospital.
Address for reprint requests: S. Horowitz, CardioPulmonary Research Institute, Suites 503-505, Winthrop-Univ. Hospital, 222 Station Plaza North, Mineola, NY 11501.
Received 4 April 1997; accepted in final form 12 December 1997.
| |
REFERENCES |
|---|
|
|
|---|
1.
Abman, S. H.,
B. A. Chatfield,
S. L. Hall,
and
I. F. McMurtry.
Role of EDRF during transition of pulmonary circulation at birth.
Am. J. Physiol.
259 (Heart Circ. Physiol. 28):
H1921-H1927,
1990
2.
Albrecht, H.,
J. Tschopp,
and
C. V. Jongeneel.
Bcl-2 protects from oxidative damage and apoptotic cell death without interfering with activation of NF-kappa B by TNF.
FEBS Lett.
351:
45-48,
1994[Medline].
3.
Beckman, J. S.,
T. W. Beckman,
J. Chen,
P. A. Marshall,
and
B. A. Freeman.
Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide.
Proc. Natl. Acad. Sci. USA
87:
1620-1624,
1990
4.
Cappelletti, G.,
C. Incani,
and
R. Maci.
Paraquat induces irreversible actin cytoskeleton disruption in cultured human lung cells.
Cell Biol. Toxicol.
10:
255-263,
1994[Medline].
5.
Finer, N. N.,
P. C. Etches,
B. Kamstra,
A. J. Tierney,
A. Peliowsky,
and
A. Ryan.
Inhaled nitric oxide in infants referred for extracorporeal membrane oxygenation: dose response.
J. Pediatr.
124:
303-308,
1994.
6.
Forrest, V. J.,
Y. H. Kang,
D. E. McClain,
D. H. Robinson,
and
N. Ramakrishnan.
Oxidative stress-induced apoptosis prevented by Troxlox.
Free Radic. Biol. Med.
16:
675-684,
1994[Medline].
7.
Frostell, C.,
M. D. Fratacci,
J. C. Wain,
R. Jones,
and
W. M. Zapol.
Inhaled nitric oxide: a selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction.
Circulation
83:
2038-2047,
1991
8.
Garat, C.,
C. Jayr,
S. Eddahibi,
M. Laffon,
M. Meignan,
and
S. Adnot.
Effects of inhaled nitric oxide or inhibition of endogenous nitric oxide formation on hyperoxic lung injury.
Am. J. Respir. Crit. Care Med.
155:
1957-1964,
1997[Abstract].
9.
Gille, J. J. P.,
C. G. M. Vanberkel,
and
H. Joenje.
Mutagenicity of metabolic oxygen radicals in mammalian cell cultures.
Carcinogenesis
15:
2695-2699,
1994
10.
Haddad, I. Y.,
H. Ischiropoulos,
B. A. Holm,
J. R. Beckman,
J. R. Baker,
and
S. Matalon.
Mechanisms of peroxynitrite-induced injury to pulmonary surfactants.
Am. J. Physiol.
265 (Lung Cell. Mol. Physiol. 9):
L555-L564,
1993
11.
Hallman, M.,
F. Waffarn,
K. Bry,
R. Turbow,
M. T. Kleinman,
W. J. Mautz,
R. E. Rasmussen,
D. K. Bhalla,
and
R. F. Phalen.
Surfactant dysfunction after inhalation of nitric oxide.
J. Appl. Physiol.
80:
2026-2034,
1996
12.
Haydar, A.,
P. Mauriat,
P. Pouard,
D. Lefebvre,
T. Malhere,
D. Journois,
N. Denis,
D. Safran,
and
P. Vouhe.
Inhaled nitric oxide for postoperative pulmonary hypertension in patients with congenital heart defects.
Lancet
340:
818-819,
1992[Medline].
13.
Ignarro, L. J.,
G. M. Buga,
K. S. Wood,
R. E. Byrns,
and
G. Chaudhuri.
Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide.
Proc. Natl. Acad. Sci. USA
84:
9265-9269,
1987
14.
Jia, L.,
C. Bonaventura,
J. Bonaventura,
and
J. S. Stamler.
S-nitrosohaemoglobin: a dynamic activity of blood involved in vascular control.
Nature
380:
221-226,
1996[Medline].
15.
Kazzaz, J.,
J. Xu,
T. Palaia,
L. Mantell,
A. M. Fein,
and
S. Horowitz.
Cellular oxygen toxicity: oxidant injury without apoptosis.
J. Biol. Chem.
271:
15182-15186,
1996
16.
Kinsella, J. P.,
S. R. Neish,
D. D. Ivy,
E. Shaffer,
and
S. H. Abman.
Clinical response to prolonged treatment of persistant pulmonary hypertension of the newborn with low doses of inhaled nitric oxide.
J. Pediatr.
123:
103-108,
1993[Medline].
17.
Laemmli, U. K.
Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
Nature
227:
680-685,
1970[Medline].
18.
Palmer, R. M. J.,
A. G. Ferrige,
and
S. Moncada.
Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor.
Nature
327:
524-526,
1987[Medline].
19.
Robbins, C. G.,
J. M. Davis,
T. A. Merritt,
J. Amirkhanian,
N. Sahgal,
F. C. Morin III,
and
S. Horowitz.
Combined effects of nitric oxide and hyperoxia on surfactant function and pulmonary inflammation.
Am. J. Physiol.
269 (Lung Cell. Mol. Physiol. 13):
L545-L550,
1995
20.
Roberts, J. D.,
D. M. Polaner,
P. Lang,
and
W. M. Zapol.
Inhaled nitric oxide in persistant pulmonary hypertension of the newborn.
Lancet
340:
818-819,
1992.
21.
Sandstrom, P. A.,
B. Roberts,
T. M. Folks,
and
T. M. Buttke.
HIV gene expression enhances T cell susceptibility to hydrogen peroxide-induced apoptosis.
AIDS Res. Hum. Retroviruses
9:
1107-1113,
1993[Medline].
22.
Sellden, H.,
P. Winberg,
L. E. Gustafsson,
B. Lundell,
K. Book,
and
C. G. Frostell.
Inhalation of nitric oxide reduced pulmonary hypertension after cardiac surgery in a 3.2-kg infant.
Anesthesiology
78:
577-560,
1993[Medline].
23.
Slater, A. F. G.,
C. S. I. Nobel,
and
S. Orrenius.
The role of intracellular oxidants in apoptosis.
Biochim. Biophys. Acta
1271:
59-62,
1995[Medline].
24.
Waldman, S. A., and F. Murad. Biochemical
mechanisms underlying vascular smooth muscle relaxation: the guanylate
cyclase-cyclic GMP system. J. Cardiovasc.
Pharmacol. 12, Suppl. 5: S115-S118,
1988.
This article has been cited by other articles:
![]() |
L. Sparkman and V. Boggaram Nitric oxide increases IL-8 gene transcription and mRNA stability to enhance IL-8 gene expression in lung epithelial cells Am J Physiol Lung Cell Mol Physiol, October 1, 2004; 287(4): L764 - L773. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Li, Y. Arita, H.-c. Koo, J. M. Davis, and J. A. Kazzaz Inhibition of c-Jun N-Terminal Kinase Pathway Improves Cell Viability in Response to Oxidant Injury Am. J. Respir. Cell Mol. Biol., December 1, 2003; 29(6): 779 - 783. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Salinas, L. Sparkman, K. Berhane, and V. Boggaram Nitric oxide inhibits surfactant protein B gene expression in lung epithelial cells Am J Physiol Lung Cell Mol Physiol, November 1, 2003; 285(5): L1153 - L1165. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Ahmad, A. Ahmad, E. Gerasimovskaya, K. R. Stenmark, C. B. Allen, and C. W. White Hypoxia Protects Human Lung Microvascular Endothelial and Epithelial-like Cells against Oxygen Toxicity: Role of Phosphatidylinositol 3-Kinase Am. J. Respir. Cell Mol. Biol., February 1, 2003; 28(2): 179 - 187. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. L. Pearce, B. R. Pitt, and J. Peterson The Peroxynitrite Reductase Activity of Cytochrome c Oxidase Involves a Two-electron Redox Reaction at the Heme a3-CuB Site J. Biol. Chem., December 10, 1999; 274(50): 35763 - 35767. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. E. Howlett, J. S. Hutchison, J. P. Veinot, A. Chiu, P. Merchant, and H. Fliss Inhaled nitric oxide protects against hyperoxia-induced apoptosis in rat lungs Am J Physiol Lung Cell Mol Physiol, September 1, 1999; 277(3): L596 - L605. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |